Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL14060961 | 0.89 | GAA (0.33) | GAAPOLBALDH1A1 | |
| SCHEMBL5905681 | 0.85 | ALDH1A1 (0.40) | GAAPOLBALDH1A1 | |
| SCHEMBL585090 | 0.74 | SLC6A12 (0.37) | GAAPOLBALDH1A1 | |
| SCHEMBL17836875 | 0.73 | CHRM2 (0.35) | GAAPOLB | |
| SCHEMBL1203112 | 0.73 | CHRM2 (0.35) | GAAPOLB | |
| Propionic Acid SCHEMBL17632248 | 0.72 | ALDH1A1 (0.66) | FFAR3POLBALDH1A1 | |
| SCHEMBL25217480 | 0.72 | POLB (0.31) | POLBALDH1A1 | |
| SCHEMBL5696179 | 0.70 | POLB (0.50) | GAAPOLBALDH1A1 | |
| SCHEMBL5696191 | 0.70 | POLB (0.50) | GAAPOLBALDH1A1 | |
| SCHEMBL821102 | 0.70 | POLB (0.50) | GAAPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3411465-A1 | COMPOSITIONS CONTAINING ANTIFOAMS | The Procter and Gamble Company (US) | 2018-12-12 | — | — | EP | claimed |
| EP-3411425-A1 | ANTIFOAM MOLECULES AND COMPOSITIONS | The Procter and Gamble Company (US) | 2018-12-12 | — | — | EP | claimed |
| WO-2017136370-A1 | COMPOSITIONS CONTAINING ANTIFOAMS | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-10 | — | — | WO | claimed |
| WO-2017136369-A1 | ANTIFOAM MOLECULES AND COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-10 | — | — | WO | claimed |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2026-05-14 | — | — | US | disclosed |
| EP-4717756-A2 | LIPASE VARIANTS AND DETERGENT COMPOSITIONS | Novozymes A/S (DK) | 2026-04-01 | — | — | EP | disclosed |
| US-12559736-B2 | Lipase variants and polynucleotides encoding same | NOVOZYMES A/S (DK) | 2026-02-24 | — | — | US | disclosed |
| US-12529017-B2 | Detergent composition comprising a lipase | NOVOZYMES A/S (DK) | 2026-01-20 | — | — | US | disclosed |
| US-20250382594-A1 | METHODS OF REDUCING ODOR | NOVOZYMES A/S (DK) | 2025-12-18 | — | — | US | disclosed |
| US-12492387-B2 | Lipase variants and microcapsule compositions comprising such lipase variants | NOVOZYMES A/S (DK) | 2025-12-09 | — | — | US | disclosed |
| US-20250368924-A1 | LIPASE VARIANTS AND COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2025-12-04 | — | — | US | disclosed |
| US-12480108-B2 | Methods of reducing odor | Novozyms A/S (DK) | 2025-11-25 | — | — | US | disclosed |
| EP-2623586-A2 | Compositions and methods for surface treatment with lipases | The Procter & Gamble Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20110041259-A1 | STABLE ODORANT SYSTEMS | LOUGHNANE BRIAN JOSEPH | 2011-02-24 | — | — | US | disclosed |
| US-20100113316-A1 | STABLE ODORANT SYSTEMS | LOUGHNANE BRIAN JOSEPH | 2010-05-06 | — | — | US | disclosed |
| EP-1954794-A2 | STABLE ODORANT SYSTEMS | The Procter and Gamble Company (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070123441-A1 | Stable odorant systems | PROCTER & GAMBLE COMPANY, THE | 2007-05-31 | — | — | US | disclosed |
| US-20070123440-A1 | Stable odorant systems | THE PROCTER & GAMBLE COMPANY | 2007-05-31 | — | — | US | disclosed |
| WO-2007060645-A2 | STABLE ODORANT SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-0746552-B1 | TETRAHYDROFURANS AND TETRAHYDROPYRANS | GIVAUDAN SA (CH) | 2002-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559736-B2 | Lipase variants and polynucleotides encoding same | LPL, PNLIP, LIPG | GAA 182/4885FFAR3 1801/4885POLB 61/4885 |
| US-20260132388-A1 | LIPASE VARIANTS AND MICROCAPSULE COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | LIPE, LPL, PNLIP | GAA 158/4885FFAR3 220/4885POLB 1126/4885 |
| US-12529017-B2 | Detergent composition comprising a lipase | MGLL, LPL, LIPC | GAA 271/4885FFAR3 297/4885POLB 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.